Comparative Pharmacology
Head-to-head clinical analysis: PANWARFIN versus SODIUM HEPARIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANWARFIN versus SODIUM HEPARIN.
PANWARFIN vs SODIUM HEPARIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anticoagulant that inhibits vitamin K epoxide reductase, thereby decreasing hepatic synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X.
Binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby preventing fibrin formation and extension of thrombi.
5 mg orally once daily, adjusted to maintain INR 2-3.
Initial IV bolus 80 units/kg followed by continuous IV infusion at 18 units/kg/hour; adjusted based on aPTT. Alternatively, subcutaneous: 333 units/kg loading dose then 250 units/kg every 12 hours.
None Documented
None Documented
Terminal elimination half-life is 20-60 hours (mean ~40 hours). Clinically, the longer half-life allows for once-daily dosing and steady-state is achieved in 5-7 days; anticoagulant effect may persist for 2-5 days after discontinuation due to depletion of vitamin K-dependent clotting factors.
Terminal elimination half-life is dose-dependent: 0.5-1.5 hours at low doses, 1.5-2.5 hours at high doses. Clinically, anticoagulant effect half-life is approximately 1-5 hours, with shorter half-life at lower doses.
Primarily renal as inactive metabolites; 60-92% of a dose is excreted in urine, with about 50% as the 7-hydroxywarfarin metabolite and the remainder as other metabolites. Biliary/fecal elimination accounts for approximately 10-20%.
Renal: negligible; primarily cleared by hepatic and reticuloendothelial system (desulfation and depolymerization). Unchanged drug not excreted in urine.
Category C
Category A/B
Anticoagulant
Anticoagulant